{"id":745602,"date":"2017-01-20T16:01:00","date_gmt":"2017-01-20T16:01:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/"},"modified":"2025-11-07T01:26:42","modified_gmt":"2025-11-07T06:26:42","slug":"merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/","title":{"rendered":"Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada),<br \/>\n      and certain of its affiliates, today announced it agreed to enter into a<br \/>\n      settlement and license agreement with Bristol-Myers Squibb Company and<br \/>\n      Ono Pharmaceutical Co., Ltd., resolving the worldwide patent<br \/>\n      infringement litigation related to the use of an anti-PD-1 antibody for<br \/>\n      the treatment of cancer, such as KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab).\n    <\/p>\n<p>\n      Under the settlement and license agreement, the company will make a<br \/>\n      one-time payment of $625 million to Bristol-Myers Squibb and provide<br \/>\n      royalties on the worldwide sales of KEYTRUDA for a non-exclusive license<br \/>\n      to market KEYTRUDA in any market in which it is approved. For global net<br \/>\n      sales of KEYTRUDA, the company will pay Bristol-Myers Squibb royalties<br \/>\n      as follows:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        6.5 percent of net sales occurring from Jan. 1, 2017 through and<br \/>\n        including Dec. 31, 2023; and\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        2.5 percent of net sales occurring Jan. 1, 2024 through and including<br \/>\n        Dec. 31, 2026.\n      <\/li>\n<\/ul>\n<p>\n      The parties also agreed to dismiss all claims in the relevant legal<br \/>\n      proceedings.\n    <\/p>\n<p>\n      \u201cToday\u2019s announcement eliminates uncertainty and enables us to continue<br \/>\n      to focus on KEYTRUDA, our immuno-oncology medicine, which is already<br \/>\n      helping thousands of patients around the world and becoming a foundation<br \/>\n      for the treatment of cancer through our industry-leading clinical<br \/>\n      development program,\u201d said Kenneth C. Frazier, chairman and chief<br \/>\n      executive officer, Merck.\n    <\/p>\n<p>\n      The $625 million payment will be recorded in the company\u2019s<br \/>\n      fourth-quarter and full-year 2016 results. This expense will be excluded<br \/>\n      from Merck\u2019s non-GAAP results.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck has been a global health care leader<br \/>\n      working to help the world be well. Merck is known as MSD outside the<br \/>\n      United States and Canada. Through our prescription medicines, vaccines,<br \/>\n      biologic therapies and animal health products, we work with customers<br \/>\n      and operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51497220&amp;newsitemid=20170120005499&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=328aa9312f5a591a795bea7cf0c67069\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51497220&amp;newsitemid=20170120005499&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=f59a07cb020b550534244283038c1ac2\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51497220&amp;newsitemid=20170120005499&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=8cb4ca6ac14bafaed57dccc24b7939a9\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51497220&amp;newsitemid=20170120005499&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=074b10cdcd34861a2bf2fa371fea9f34\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51497220&amp;newsitemid=20170120005499&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=ebac49c14400e5333dcfef60b9ff662d\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51497220&amp;newsitemid=20170120005499&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=3b4e7e4b4ce4616a4bfc263f374ef20d\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170120005499r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/> Media: <br \/>Pamela Eisele, 267-305-3558<br \/>Claire        Gillespie, 267-305-0932<br \/>or<br \/> Investors: <br \/>Teri Loxam,        908-740-1986<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA \u00ae (pembrolizumab). Under the settlement and license agreement, the company will make a one-time payment of $625 million to Bristol-Myers Squibb and provide royalties on the worldwide sales of KEYTRUDA for a non-exclusive license to market KEYTRUDA in any market in which it is approved. For global net sales of KEYTRUDA, the company will pay Bristol-Myers Squibb royalties as follows: 6.5 percent of net sales occurring from Jan. 1, 2017 through and including Dec. 31, 2023; and 2.5 percent of net sales occurring Jan. 1, 2024 through and including Dec. 31, 2026. The parties also agreed to dismiss all claims<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745602","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA \u00ae (pembrolizumab). Under the settlement and license agreement, the company will make a one-time payment of $625 million to Bristol-Myers Squibb and provide royalties on the worldwide sales of KEYTRUDA for a non-exclusive license to market KEYTRUDA in any market in which it is approved. For global net sales of KEYTRUDA, the company will pay Bristol-Myers Squibb royalties as follows: 6.5 percent of net sales occurring from Jan. 1, 2017 through and including Dec. 31, 2023; and 2.5 percent of net sales occurring Jan. 1, 2024 through and including Dec. 31, 2026. The parties also agreed to dismiss all claims\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\\\/\",\"name\":\"Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-01-20T16:01:00+00:00\",\"dateModified\":\"2025-11-07T06:26:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA \u00ae (pembrolizumab). Under the settlement and license agreement, the company will make a one-time payment of $625 million to Bristol-Myers Squibb and provide royalties on the worldwide sales of KEYTRUDA for a non-exclusive license to market KEYTRUDA in any market in which it is approved. For global net sales of KEYTRUDA, the company will pay Bristol-Myers Squibb royalties as follows: 6.5 percent of net sales occurring from Jan. 1, 2017 through and including Dec. 31, 2023; and 2.5 percent of net sales occurring Jan. 1, 2024 through and including Dec. 31, 2026. The parties also agreed to dismiss all claims","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:42+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/","name":"Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-01-20T16:01:00+00:00","dateModified":"2025-11-07T06:26:42+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-settlement-and-license-agreement-resolving-keytruda-pembrolizumab-patent-litigation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Settlement and License Agreement Resolving KEYTRUDA\u00ae (pembrolizumab) Patent Litigation"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"25a28ea3-dafb-4fe4-a78d-6e0b7ec3a613","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745602\/revisions"}],"predecessor-version":[{"id":3674969,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745602\/revisions\/3674969"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745602"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}